病毒样颗粒疫苗的生产及其在临床应用中的研究进展

发布时间：2018-01-10 11:19

本文关键词：病毒样颗粒疫苗的生产及其在临床应用中的研究进展　出处：《现代预防医学》2017年05期 　论文类型：期刊论文

【摘要】：病毒样颗粒(Virus-like particles,VLPs)是由一个或多个病毒结构蛋白组成的纳米级颗粒。它不含病毒的遗传物质而失去感染性,但保留了天然病毒衣壳相似的免疫原性,被用于疫苗的研发与生产。与天然病毒类似,VLPs可以分为无囊膜及囊膜两种类型,它们均能在异源表达系统表达病毒结构蛋白时自装配而形成,且能够直接作为疫苗或作为展示平台构建疫苗以预防相应疾病。根据VLPs的复杂程度,可以在适当的原核、真核或无细胞表达系统下生产。目前,已经有多种针对病毒、细菌、寄生虫、真菌的VLPs疫苗在不同的表达载体上被成功构建,其中部分疫苗已经商品化,另一些则进入不同的临床阶段。本文主要综述了VLPs疫苗表达系统及VLPs疫苗作为商业医疗产品的临床发展现状及其面临的挑战。
[Abstract]:Virus-like particles. VLPsare nanoparticles of one or more viral structural proteins that contain no genetic material from the virus and lose their infectivity, but retain the immunogenicity similar to that of the natural viral capsid. Similar to natural viruses, VLPs can be classified into two types: envelope free and envelope free, which can be self-assembled when expressing structural proteins in heterologous expression systems. And can be used as a vaccine or as a display platform to construct vaccines to prevent the corresponding diseases. According to the complexity of VLPs, can be produced under the appropriate prokaryotic, eukaryotic or cell-free expression system. A variety of VLPs vaccines against viruses, bacteria, parasites and fungi have been successfully constructed on different expression vectors, some of which have been commercialized. In this paper, the expression system of VLPs vaccine and the clinical development of VLPs vaccine as a commercial medical product are reviewed.
【作者单位】：淄博市疾病预防控制中心;山东理工大学;
【基金】：山东省医药卫生科技发展计划项目(No.2015WS0007)资助
【分类号】：R392
【正文快照】： 疫苗是控制和预防人类疾病最有效的方式之一。传统疫苗主要使用灭活或减毒的病原体制成,为人类消灭了诸如天花等疾病,但是经常伴随着一些副作用而存在安全隐患[1]。近年来,随着DNA重组技术与基因工程的发展和人们对免疫反应认识的加深,各种新型疫苗相继出现,人用疫苗进入了发

【相似文献】